Literature DB >> 27531684

Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.

Sherean Farvardin1, Jaimin Patel1, Maleka Khambaty1, Olutola A Yerokun1, Huram Mok1, Jasmin A Tiro2,3, Adam C Yopp2,4, Neehar D Parikh5, Jorge A Marrero1, Amit G Singal1,2,3.   

Abstract

Over 20% of patients with cirrhosis are nonadherent with hepatocellular carcinoma (HCC) surveillance recommendations; however, few studies have evaluated the impact of patient-level factors on surveillance receipt. We characterized the association between HCC surveillance receipt and patient knowledge, attitudes, and perceived barriers in a racially diverse and socioeconomically disadvantaged cohort of patients with cirrhosis. Patients with cirrhosis followed at a large urban hospital were invited to complete a survey about HCC surveillance between August 2014 and December 2015. Multivariable logistic regression was performed to identify factors associated with HCC surveillance receipt during the 12-month period preceding and 6-month period after survey administration. We achieved a response rate of 71.8% (n = 541 of 753). Patients demonstrated high levels of HCC-related knowledge (summary score, 77.7%); however, 48.6% believed that eating a healthy diet precluded the need for HCC surveillance, and 34.0% believed that HCC surveillance was not necessary if they had a normal physical exam and/or lacked clinical symptoms. Patients expressed worry about developing and dying from HCC, but nearly half (49.9%) of patients reported barriers to receiving HCC surveillance, including difficulty with the scheduling process (30.5%), costs of surveillance testing (25.3%), and transportation difficulties (17.3%). HCC surveillance receipt was significantly higher in patients who knew cirrhosis is a risk factor for developing HCC (odds ratio [OR], 3.09; 95% confidence interval [CI], 1.25-7.62) and significantly lower in those reporting barriers to surveillance (OR, 0.42; 95% CI, 0.25-0.70).
CONCLUSION: Patients with cirrhosis are knowledgeable and interested in HCC surveillance; however, patient-reported barriers are associated with lower surveillance rates in clinical practice and represent potential intervention targets to improve HCC surveillance effectiveness. (Hepatology 2017;65:875-884).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27531684      PMCID: PMC5568252          DOI: 10.1002/hep.28770

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Socioeconomic status and hepatocellular carcinoma in the United States.

Authors:  Fatma M Shebl; David E Capo-Ramos; Barry I Graubard; Katherine A McGlynn; Sean F Altekruse
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-05       Impact factor: 4.254

2.  Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma.

Authors:  Amit G Singal; Michael L Volk; Mina O Rakoski; Sherry Fu; Grace L Su; Heather McCurdy; Jorge A Marrero
Journal:  J Clin Gastroenterol       Date:  2011-09       Impact factor: 3.062

Review 3.  Recent advances in the treatment of hepatocellular carcinoma.

Authors:  Amit G Singal; Jorge A Marrero
Journal:  Curr Opin Gastroenterol       Date:  2010-05       Impact factor: 3.287

4.  Failure rates in the hepatocellular carcinoma surveillance process.

Authors:  Amit G Singal; Adam C Yopp; Samir Gupta; Celette Sugg Skinner; Ethan A Halm; Eucharia Okolo; Mahendra Nehra; William M Lee; Jorge A Marrero; Jasmin A Tiro
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-30

Review 5.  Perspectives on behavioral and social science research on cancer screening.

Authors:  William Rakowski; Erica S Breslau
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

6.  Constructing a theoretically based set of measures for liver cancer control research studies.

Authors:  Annette E Maxwell; Roshan Bastani; Moon S Chen; Tung T Nguyen; Susan L Stewart; Vicky M Taylor
Journal:  Prev Med       Date:  2009-10-31       Impact factor: 4.018

7.  Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening.

Authors:  Amit G Singal; Jasmin A Tiro; Samir Gupta
Journal:  Clin Gastroenterol Hepatol       Date:  2012-11-28       Impact factor: 11.382

8.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  Cancer screening adherence: does physician-patient communication matter?

Authors:  Sarah A Fox; John Heritage; Susan E Stockdale; Steven M Asch; Naihua Duan; Steven P Reise
Journal:  Patient Educ Couns       Date:  2009-02-27

10.  Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States.

Authors:  Avo Artinyan; Brian Mailey; Nicelio Sanchez-Luege; Joshua Khalili; Can-Lan Sun; Smita Bhatia; Lawrence D Wagman; Nicholas Nissen; Steven D Colquhoun; Joseph Kim
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

View more
  56 in total

1.  Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.

Authors:  Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-05-31       Impact factor: 11.382

Review 2.  Surveillance for hepatocellular cancer.

Authors:  Anna Roskilly; Ian A Rowe
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

Review 3.  Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.

Authors:  Shreya Sengupta; Neehar D Parikh
Journal:  Hepat Oncol       Date:  2017-11-17

4.  Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis.

Authors:  Winston E Abara; P Spradling; Y Zhong; A Moorman; E H Teshale; L Rupp; S C Gordon; M Schmidt; J A Boscarino; Y G Daida; S D Holmberg
Journal:  J Gastrointest Cancer       Date:  2020-06

Review 5.  Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies.

Authors:  N Merchante; M Rodríguez-Fernández; J A Pineda
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

6.  Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.

Authors:  Charlotte E Costentin; Philippe Sogni; Bruno Falissard; Jean-Claude Barbare; Noelle Bendersky; Olivier Farges; Nathalie Goutte
Journal:  Dig Dis Sci       Date:  2019-07-25       Impact factor: 3.199

7.  Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.

Authors:  Hesam Tavakoli; Ann Robinson; Benny Liu; Taft Bhuket; Zobair Younossi; Sammy Saab; Aijaz Ahmed; Robert J Wong
Journal:  Dig Dis Sci       Date:  2017-05-04       Impact factor: 3.199

Review 8.  Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance.

Authors:  Julie Y An; Miguel A Peña; Guilherme M Cunha; Michael T Booker; Bachir Taouli; Takeshi Yokoo; Claude B Sirlin; Kathryn J Fowler
Journal:  Radiographics       Date:  2020 Nov-Dec       Impact factor: 5.333

9.  Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial.

Authors:  Amit G Singal; Jasmin A Tiro; Caitlin C Murphy; Jorge A Marrero; Katharine McCallister; Hannah Fullington; Caroline Mejias; Akbar K Waljee; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm
Journal:  Hepatology       Date:  2018-12-14       Impact factor: 17.425

Review 10.  Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.

Authors:  Lisa X Deng; Neil Mehta
Journal:  Dig Dis Sci       Date:  2020-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.